Neurogene (NGNE) Stock Forecast, Price Target & Predictions
NGNE Stock Forecast
Neurogene stock forecast is as follows: an average price target of $52.00 (represents a 201.80% upside from NGNE’s last price of $17.23) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
NGNE Price Target
The average price target for Neurogene (NGNE) is $52.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $45.00. This represents a potential 201.80% upside from NGNE's last price of $17.23.
NGNE Analyst Ratings
According to 3 Wall Street analysts, Neurogene's rating consensus is 'Buy'. The analyst rating breakdown for NGNE stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Neurogene Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 19, 2024 | Keith Tapper | BMO Capital | $45.00 | $35.59 | 26.44% | 161.17% |
| Nov 12, 2024 | Keith Tapper | BMO Capital | $60.00 | $64.48 | -6.95% | 248.23% |
| Nov 12, 2024 | Paul Matteis | Stifel Nicolaus | $60.00 | $64.48 | -6.95% | 248.23% |
| Aug 12, 2024 | Mitchell Kapoor | H.C. Wainwright | $49.00 | $35.59 | 37.68% | 184.39% |
| Jun 26, 2024 | Keith Tapper | BMO Capital | $65.00 | $32.01 | 103.06% | 277.25% |
| Jun 10, 2024 | Joel Beatty | Robert W. Baird | $54.00 | $37.35 | 44.58% | 213.41% |
| May 13, 2024 | Mitchel Kapoor | H.C. Wainwright | $51.00 | $30.26 | 68.54% | 196.00% |
The latest Neurogene stock forecast, released on Nov 19, 2024 by Keith Tapper from BMO Capital, set a price target of $45.00, which represents a 26.44% increase from the stock price at the time of the forecast ($35.59), and a 161.17% increase from NGNE last price ($17.23).
Neurogene Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 3 | 3 | 7 |
| Avg Price Target | $55.00 | $55.00 | $54.86 |
| Last Closing Price | $17.23 | $17.23 | $17.23 |
| Upside/Downside | 219.21% | 219.21% | 218.40% |
In the current month, the average price target of Neurogene stock is $55.00, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 219.21% increase as opposed to Neurogene's last price of $17.23. This month's average price target is down 0.00% compared to last quarter, and up 0.26% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 16, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 14, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 26, 2024 | BMO Capital | - | Outperform | Initialise |
| Jun 20, 2024 | William Blair | Outperform | Outperform | Hold |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Neurogene's last stock rating was published by BMO Capital on Oct 16, 2024. The company gave NGNE a "Outperform" rating, the same as its previous rate.
Neurogene Financial Forecast
Neurogene Revenue Forecast
| Revenue |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| # Analysts |
| Surprise % |
Neurogene's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NGNE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Neurogene EBITDA Forecast
| # Analysts |
| EBITDA |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
undefined analysts predict NGNE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Neurogene's previous annual EBITDA (undefined) of $NaN.
Neurogene Net Income Forecast
| # Analysts |
| Net Income |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Neurogene's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NGNE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Neurogene SG&A Forecast
| # Analysts |
| SG&A |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Neurogene's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NGNE last annual SG&A of $NaN (undefined).
Neurogene EPS Forecast
| # Analysts |
| EPS |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
According to undefined Wall Street analysts, Neurogene's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NGNE previous annual EPS of $NaN (undefined).